BPC-157 is a peptide primarily investigated for its regenerative potential, particularly in musculoskeletal and gastrointestinal healing. Preclinical evidence and early human trials suggest it may accelerate recovery from injuries, improve tissue quality, and enhance outcomes in conditions like tendinopathies and muscle strains. TB-500, a synthetic version of Thymosin Beta-4, is also explored for its regenerative and anti-inflammatory properties, with a focus on tissue repair and healthy aging. Both peptides are considered therapeutic agents with potential applications in regenerative medicine and sports recovery, aiming to improve healing and reduce recovery times.
| BPC-157 | TB-500 | |
|---|---|---|
| Drug class | healing peptide, gastric pentadecapeptide | healing peptide, thymosin |
| Studies in corpus | 107 | 17 |
| Highest evidence tier | meta analysis | review |
| Evidence tier mix | review · 20 other · 10 in vitro · 5 preclinical animal · 67 rct · 3 meta analysis · 1 | review · 6 in vitro · 3 other · 6 preclinical animal · 2 |
| Studies with explicit sample size | 1 | 0 |
| Head-to-head studies in corpus | 4 | |
Studies in our corpus that mention both BPC-157 and TB-500 — the gold-standard direct comparison evidence.
This review underscores the significant promise of injectable therapeutic peptides as novel tools in regenerative medicine and sports performance. Their ability to accelerate healing, reduce inflammation, and promote tissue regeneration could revolutionize …
This review underscores the transformative potential of therapeutic peptides to address unmet needs in orthopaedic medicine. By offering targeted biological interventions, peptides could significantly improve patient outcomes, reduce recovery times, and pro…
This research provides critical tools for anti-doping laboratories to predict and identify peptide metabolites, significantly improving detection windows for prohibited substances. By understanding the metabolic fate of these peptides, new analytical method…
This research provides critical insights into the in vitro metabolic pathways of synthetic doping peptides, which is essential for developing robust and sensitive anti-doping tests. The identification of liver S9 fraction as a superior model for mimicking i…
No direct head-to-head trials in our corpus. Indirect comparison only. BPC-157 has a more extensive body of research in our corpus, with 109 studies, including several human clinical trials. A pilot study established the safety and tolerability of intravenous BPC-157 in healthy humans at doses up to 10 µg/kg, and a Phase 1 trial for oral BPC-157 has been completed. A Phase 2 trial is also underway for acute hamstring strain repair. Evidence suggests BPC-157's potential in orthopaedic sports injuries and various musculoskeletal conditions. TB-500 has fewer studies in our corpus (19 total) and its human clinical trial data is less prominent in the indexed literature. Reviews highlight its potential in regenerative medicine and healthy aging, and there is an expanding patent landscape for thymosin peptides, indicating commercial and clinical interest. However, a review specifically noted that TB-500, along with BPC-157, lacks robust human orthopaedic evidence to support routine use in orthopaedic settings based on current high-quality data.
Looking for vendor-level purity, endotoxin, and HPLC data on BPC-157 or TB-500? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.